Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE003 (CAN) (Dr. Okafor)
· consented 2023-06-19
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-07-17 (study day 10); relationship: N
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-24 (study day 79); relationship: N
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-27 (study day 173); relationship: N
severe
serious
assessed
2026-08-18
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-02-16 (study day 224); relationship: N; serious criteria: hospitalization
severe
assessed
2026-08-18
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-07 (study day 244); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-19 (study day 256); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.